Optic Pathway Glioma


Tumour Group: Gliomas and Pediatric Brain Tumours
WHO Grade:

Optic pathway gliomas (OPG) are generally very low-grade tumours.

Grade I pilocytic astrocytoma and grade II fibrillary (diffuse) astrocytoma are the most common tumours affecting these structures.

It would be unusual to have a high-grade tumour in this location.

Prevalence/Incidence: 5% of all childhood intracranial tumours are optic pathway gliomas.
Typical Age Range: Occurs most often in infants and children under the age of 10, but can occur in adults.

Description of Tumour
Treatment / Standard of Care

Description of Tumour

Like many brain tumour types, the exact cause of an optic pathway glioma is unknown. However, optic pathway gliomas are associated with neurofibromatosis type 1 (NF-1), also called Von Recklinhausen’s disease.

  • 20% of children with neurofibromatosis (NF-1) will develop an optic glioma.
  • These gliomas are typically grade I pilocytic astrocytomas.
  • Children with optic glioma are usually screened for NF-1 for this reason.
  • Adults with NF-1 typically do not develop optic gliomas.

This tumour type is named for its location on or near the optic nerve pathways between the eyes and the brain. These tumours may involve any part of the optic pathway and have the potential to spread along these pathways.


Common symptoms include:

  • Behavioural disturbance
  • Clumsy, uncoordinated walk
  • Developmental delay(s), or early puberty due to hormonal disturbance
  • Double vision, also called strabismus (crossed eyes)
  • Failure to thrive in very young children
  • Headaches
  • Visual disturbance/loss (children may fall or bump into things more easily because of this symptom and may not complain directly that their vision has changed)

Treatment / Standard of Care

The treatment of an OPG depends very much on the location and extent of the tumour. Not all patients with identifiable optic pathway gliomas on imaging ever have visual symptoms (especially if the patient has NF-1).

Spontaneous regression of these tumours has been documented (in patients with and without NF-1). 

In many patients with mild symptoms, observation alone may be recommended because:

  • Symptoms are mild and there is no immediate threat to vision.
  • The natural history of disease is most likely very slow (as with patient with NF-1).
  • The patient is young and the aim is to reduce the risk of treatment related morbidity.

Surgical treatment for OPG may involve either biopsy or excision of the tumour. Surgery is usually the first choice when:

  • Single nerve involvement is causing progressive disfiguring proptosis (bulging out of the eye) and blindness.
  • An exophytic tumour involving the optic chiasm is causing mass effect or hydrocephalus (raised intracranial pressure).

Chemotherapy has the ability to shrink OPG and may even stabilize the tumour. This treatment is often given to very young children to delay giving radiation therapy and avoid damage to the developing brain.

Moderately high-dose radiation therapy can be used to control these tumours. Different techniques can be used to spare surrounding normal structures such as stereotactic radiation therapy.


A prognosis is an estimate of the likely progress of a disease after a diagnosis, based on an average patient group. Since every person is different, please take time to talk with your health care team about how this information applies to you.

By clicking on 'Expand,' a statistic on the prognosis for optic pathway gliomas will be shown.

Expand for Prognosis Information

For brain tumour patients, a prognosis depends on several factors, which can include age and other health issues, the size of the tumour, its molecular profile, the type of tumour, how much can be removed and its response to treatments such as chemotherapy and radiation therapy.

Optic pathway gliomas that are considered Grade I tend to have the most favourable survival rates compared to other higher grade brain tumours. 


Adult Brain Tumour Handbook 6th Edition. Brain Tumour Foundation of Canada. 2012.

Louis, David N. WHO Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer, 2007. Print

"Optic Nerve Gliomas in Children." Johns Hopkins Medicine, Based in Baltimore, Maryland. John Hopkins Medicine, n.d. Web. 11 July 2013.

Pediatric Brain Tumour Handbook 6th Edition. Brain Tumour Foundation of Canada. 2012.

Image credited to The Armed Forces Institute of Pathology [Public domain], via Wikimedia Commons


You can also download this information as a Information Sheet on Optic Pathway Glioma (pdf).



Share This

Featured Story

Make every brain tumour count

Stephanie, a 38-year-old mother of twins has been diagnosed with an extremely rare and inoperable brain tumour - a rosette-forming glioneuronal tumour, a type of tumour that little is known about and cannot be removed due to its location in her brain. This reality does not stop Stephanie from her tireless efforts to reduce the stigma of having a brain tumour. Learn why Stephanie is urging all Canadians to make every brain tumour count.

Learn more


Piper's Story: a dream more precious than Olympic gold

Hi, I am Piper Gilles. You may know me as a world-famous ice dancer. I competed in the PyeongChang 2018 Olympic Winter Games. I am a 7...

Learn more

Doug's Adventure

I am Doug, I have brain cancer; I am told it is terminal, but the “good” kind of terminal. I can assure you that receiving that news...

Learn more

Upcoming Events

  • 17/Jul/2019: Niagara Region Support Group: Meets at Wellspring Niagara, 3250 Schmon Parkway, Thorold, ON, L2V 4Y6... Learn more >
  • 18/Jul/2019: Virtual Support Group East: Virtual Support Group for Eastern Canada... Learn more >
  • 20/Jul/2019: Rebounders - LdnOnt: First Baptist Church, 568 Richmond St, London, ON... Learn more >
  • 20/Jul/2019: BrainWAVE ON 2019 Toronto Football: BMO Field Exhibition Place, Toronto, ON... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2019 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001